BrightOwl Loader Loading

Summary

Advice and Interim Management within LifeSciences and Agro&Food sectors. Executive with more than 30 years international experience in management of Discovery, R&D, Regulatory Affairs and Manufacturing of Vaccines and Pharmaceuticals. Areas of consultancy: Strategic direction, Change management, R&D structure, Innovation Programs, Portfolio analysis, Regulatory Strategies, M&A. Non-Executive Board memberships

Experiences

Current Experience

  • Member Technical Advisory Committee
    Since November 2014

  • Member Scientific Advisory Board
    Since January 2014
    The Jenner Institute is a research partnership between the University of Oxford and The Pirbright Institute. The Institute focuses on the parallel development of human and veterinary vaccines against major global diseases - from early-stage research through to clinical trials.

  • Owner
    Since December 2012
    Major activitiy is advising senior management of top tier global Animal Health companies and selected other parties on topics of strategic interest. This includes support on M&A projects. Non-Executive (advisory) Board Member of companies and institutions active in the field of Life Sciences and AgroFood. Support of Start-up companies active in these areas. Spoke at the kick-off Symposium of the Future Food program of the University of Utrecht in April 2015. Title: Animal Health, key for Future Food.

  • Member Board of Directors
    Since January 2011

Past Experience

  • Interim Managing Director
    September 2014 --- May 2015
    Lead the high performance team of global experts in feed research and animal physiology during the period until a new Managing Director/CEO of SFR BV has been found and appointed.

  • Vice President Animal Health, R&D Biologicals
    February 2008 --- November 2012
    Member of the Animal Health Executive Team, responsible for leading the Global Biologicals R&D of the world leader in veterinary vaccines. A consistent top class pipeline and effectively bringing innovations to the market are key characteristics of the R&D team.

  • Chairman Roadmap One Health
    August 2011 --- October 2012

  • Senior Director Operations, the Netherlands
    January 2005 --- March 2008
    Led the largest Manufacturing and Logistics unit within Intervet-SP. More than 800 fte producing antigens, vaccines and pharmaceuticals for the global market. Initiated major organisational change program leading to both improved quality and output as well as improved COG's.

  • Director R&D The Netherlands
    February 2002 --- May 2005

  • Global Head Regulatory Affairs
    January 1996 --- February 2002

  • Head Antibiotics R&D
    January 1990 --- December 1996

  • Head Veterinary Drugs
    January 1984 --- January 1990

  • Head Analytical Chemistry
    January 1980 --- February 1984

Knowledge

LinkedIn Assessment :
Regulatory affairsR&DPharmaceutical IndustryBiotechnologyLifesciencesGMPClinical trialsClinical DevelopmentTechnology transferVaccinesMicrobiologyBiopharmaceuticalsInfectious diseasesVeterinary MedicineCellELISAStrategyBiochemistryImmunologyscienceLife Sciences

Education

  • in Senior Executive Challenge of Leadership program from INSEAD in 2009
  • PhD in Bioanalytics and Pharmacochemistry from Free University of Amsterdam in 1990
  • MSc in Pharmacochemistry & Organic Chemistry from Radboud Universiteit Nijmegen in 1980

Area / Region

Boxmeer, Netherlands

Others

Driving License
  • No